Phase 2 Study of RT001 in ALS Patients Fully Enrolled, Retrotope Says

Phase 2 Study of RT001 in ALS Patients Fully Enrolled, Retrotope Says

293809

Phase 2 Study of RT001 in ALS Patients Fully Enrolled, Retrotope Says

A Phase 2 clinical trial evaluating oral RT001 — Retrotope’s experimental synthetic fatty acid — as a treatment of amyotrophic lateral sclerosis (ALS) is fully enrolled, the company announced. The enrollment target of 40 patients was met, and exceeded, ahead of its scheduled six weeks. Dosing began in this Phase 2 study (NCT04762589) in March, and Retrotope expects that trial data to be available by year’s end. “Patients living with ALS are in need of new and improved treatment…

You must be logged in to read/download the full post.